ACLX Arcellx Therapeutics Earnings per share growth rate in current year

ACLX (Arcellx Therapeutics) - company brandmark

Amidst the fierce competition for leadership in cell therapy, the GURU.Markets terminal chart for Arcellx (ACLX) shows earnings per share growth compared to last year, where the 14.70 metric confirms the current level. This price action reflects the success of myeloma treatment trials, while the operating model relies on outsourcing CAR-T drug production to certified plants.

ACLX - Arcellx, Inc. Earnings growth in current year over the range 04/28/2023 - 05/09/2026

Financial and market metric breakdowns for Arcellx (ACLX)

- stock value and consensus price forecast:
Market Price Arcellx Inc|ACLX - Price Target Chart
- market capitalization data:
Market Value Arcellx Therapeutics|ACLX - Enterprise Value
- balance sheet equity data:
Equity per Share Arcellx|ACLX - Book Capitalization|Market Capitalization to Book Value Ratio arcellx.com|ACLX - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Arcellx|ACLX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio arcellx.com|ACLX - Company Aggregate Debts|Debts to Book Value Arcellx Therapeutics|ACLX - Company Long-Term Debt|Company Short-Term Debt Arcellx|Quick Liquidity arcellx.com
- earnings and market ratios statistics:
ACLX - Net Income|Net Profit Forecast Arcellx|ACLX - P/E Multiple|Forward P/E Multiple Arcellx Therapeutics|ACLX - PEG Multiple|Enterprise Value to EBITDA Ratio Arcellx Therapeutics|ACLX - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Arcellx|ACLX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months arcellx.com|ACLX - Earnings growth in current year|Expected earnings per share growth for next year Arcellx
Fundamental valuation:ACLX Arcellx Inc
Manufactured products of Arcellx, Inc.

This indicator tracks the percentage change in net income per share over a twelve-month period, allowing for an assessment of business scaling rates prior to the publication of final reports. By analyzing the annual dynamics of net income per share, an investor can observe the capital burn rate on R&D, which is critical for Arcellx (ACLX) due to the absence of commercial sales and the high risks associated with the development of CAR-T therapy.

Main competitors

Earnings per share growth rate in current year TG Therapeutics Inc (TGTX)|Earnings per share growth in current year Disc Medicine Corp|Earnings per share growth rate in current year Syndax Corp SNDX|Earnings growth in current year KURA|adctherapeutics.com - Earnings per share growth this year|Earnings growth in current year FHTX (Foghorn Therapeutics Inc.)|Earnings growth in current year Vor Biopharma, Inc. VOR|NKTX - Earnings per share growth in current year|Earnings per share increase in current year COEP (Coeptis Therapeutics)|ATNM: Earnings growth in current year|Net earnings per share growth this year estrellabio.com|CASI (CASI Pharmaceuticals Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Marker Bio MRKR|Earnings per share growth in current year IN8bio, Inc (INAB)|Earnings per share growth in current year ERNA (eternatx.com)|Earnings per share growth in current year GT Biopharma, Inc. GTBP|Aptose Biosciences Inc - Earnings per share growth in current year|BPTH: Net earnings per share growth this year|MEIP (MEI Pharma Inc) - Earnings per share growth this year|VINC: Earnings growth in current year